Screener / SEC EDGAR /CIK 0001802768 /10-K filed Feb 11, 2026, compared with Feb 12, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Royalty Pharma plc RPRX

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of RPRX's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Mar 28, 2025
Questions asked 74 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 8 UPLOAD
  2. 2. Questions in them 74 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 2 of 3 closing letter

Half the closed reviews took 216 days or less from the first letter to the closing letter.

Form 10-K for the year ended December 31, 2024

2025-03-28 to 2025-04-09 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2025-04-09
Results discussion (MD&A)Critical estimates
Management's Discussion and Analysis · Critical Accounting Policies and Use of Estimates, page 71
SEC asked
You disclose on page 99 that in 2024 you refined your methodology to value your financial royalty assets. Please address the following regarding this change in methodology, with a view to revising your disclosures in future filings: • Identify and to the extent possible quantify how this change impacted your valuation of financial royalty assets in 2024 and in subsequent periods compared to your previously used
Rest of the question

methodology. Refer to Item 303(b)(3). • You disclose that your decision to begin using the Monte Carlo model "given the growing complexity of the portfolio." Explain how your use of the model impacts the valuation outcomes for your traditional royalty assets compared to your synthetic royalty assets. • As part of your response, please provide your proposed disclosure changes to be made in future filings.

RPRX answered
to the Staff’s comment in the first bullet of Comment 1 regarding the impact due to the change in the valuation methodology and reference to Item 303(b)(3), the Company respectfully advises the Staff that the disclosure of fair value on page 99 of its Form 10-K does not impact the Company’s financial condition or results of operations. The Company accounts for its financial royalty assets under ASC 310 and measures them at amortized cost using the prospective effective interest method described in ASC 835.
Rest of the answer

The Company only discloses the fair value for such assets following the rules prescribed by ASC 825-10-50-10 through 50-15. Because financial royalty assets

Ms. Sasha Parikh and Mr. Kevin Vaughn

Division of Corporation

Finance are not accounted for at fair value, the requirements in Item 303(b)(3) are not directly applicable to the disclosure of the fair value of such assets, nor the impact of the 2024 methodology change from a discounted cash flow to a Monte-Carlo model to derive the fair value disclosed. The Company respectfully advises the Staff that the adoption of the Monte-Carlo model in 2024 did not have a material impact in the determination of fair value, which resulted in an increase to the disclosed fair value of approximately 6% compared to the Company’s legacy discounted cash flow approach for 2024.

In response to the Staff’s comment in the second bullet of Comment 1 regarding the Monte-Carlo model’s impact to the valuation outcomes for traditional versus synthetic royalty assets, the Company respectively advises the Staff that the reference to traditional or synthetic royalty assets only relates to the origin of a royalty asset and not to its economic features or complexity. A traditional royalty asset refers to the acquisition of an existing contractual right to a payment based on a percentage of top-line sales from a licensee’s use of a product, technology or intellectual property. These may also be generated through other forms of legal contracts other than license agreements, such as collaboration arrangements, asset acquisitions, or legal settlements. A synthetic royalty asset is a newly created contractual right to a percentage of top-line sales payable by the developer or marketer of a therapy to a royalty investor in exchange for funding. The unique attributes of a royalty asset’s economic terms, which may include royalty tiers, milestone payments, caps and floors, are more impactful to the valuation under a Monte-Carlo framework as opposed to its characterization as a traditional vs. synthetic royalty asset. As royalty monetization transactions continue to gain acceptance in the biopharma sector and the Company’s portfolio grows to include more complex financial royalty assets, the Company believes the Monte-Carlo Approach captures the significant uncertainty and variability associated with these option-like features.

To improve the clarity of the fair value disclosure for financial royalty assets, we plan to expand the fair value disclosure going forward starting in our Form 10-Q for the quarter ended March 31, 2025, as follows:

Fair Value Disclosure of Financial Assets Not Measured at Fair Value

Financial royalty assets are not measured at fair value. Instead, they are measured and carried at amortized cost using the effective interest method on the condensed consolidated balance sheets. Financial royalty assets do not include our entire portfolio of investments, and specifically exclude the following:

development-stage product candidates where the funding was (i) expensed as upfront R&D upon acquisition (e.g., Trodelvy and Nurtec ODT), (ii) expensed as ongoing R&D (e.g., our funding arrangement for litifilimab with Biogen) or (iii) treated as a derivative instrument (e.g.,

CK-586); and contractual funding arrangements (e.g., the MorphoSys Development Funding Bonds and the Cytokinetics Funding

Arrangements), which are accounted for as available for sale debt securities.

We used a Monte Carlo simulation under the option pricing framework to calculate the fair value of our portfolio of financial royalty assets for disclosure as of March 31, 2025 and December 31, 2024. In 2024, we refined our methodology to calculate the fair value given the growing complexity of our royalty investments, which may include features such as milestone payments, royalty tiers, caps, and floors that could alter the cash flows based on future commercial, clinical, or regulatory outcomes.

The Monte Carlo model allows us to simulate a range of different outcomes based on various inputs, primarily the underlying projected product sales of each royalty bearing product, to project the cash flows, including royalty receipts and milestone payments, based on each of the simulated sales scenarios. The Monte Carlo methodology also takes volatility at the sales level into consideration. The fair value of financial royalty assets disclosed herein is classified as Level 3 within the fair value hierarchy since it is determined based on inputs that are both significant and unobservable.

Read in the reply
In its next report

First report after the company's reply of Apr 4, 2025: 10-Q filed May 8, 2025 ↗, against the 10-Q filed Nov 6, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2025-04-09

Form 10-K for the period ended December 31, 2022

2023-06-28 to 2024-01-30 · 7 questions · 3 letters from the SEC, 3 from the company
Review closed 2024-01-30
Non-GAAP measuresLiquidity and cashDebtResults discussion (MD&A)
Non-GAAP Financial Results, page 68
SEC asked (1)
In order to get a better understanding of your non-GAAP measures and presentation, please address the following in your response and in proposed revised disclosure as applicable: • As Total royalty receipts does not appear to be the most directly comparable GAAP- basis measure for your non-GAAP measures, please tell us how your presentation complies with Item 10(e)(1)(i)(B) of Regulation S-K.
Rest of the question

• On page 53, you state that Adjusted EBITDA, which is derived from Adjusted Cash Receipts, is used by your lenders to assess your ability to meet your financial covenants. You also note on page 73 that Adjusted EBITDA is critical to the assessment of the company's liquidity. In this regard in future filings, o relocate your presentations of Adjusted EBITDA to your Liquidity and Capital Resources section, and o revise the presentation for the calculation of Adjusted EBITDA to more strictly reflect its definition as found in the credit agreement. Refer to Question 102.09 of the Compliance & Disclosure Interpretations regarding Non- GAAP Financial Measures.

RPRX answered
As requested in the Staff’s Comment 1, below is a tabular breakdown of the Company’s calculation of Adjusted EBITDA, defined in the Company’s

Credit Agreement as Consolidated EBITDA, with each individual component in such definition quantified. In response to the Staff’s prior comment letter dated June 28, 2023, the Company respectfully advises the Staff that it has stated on page 43 of its Form 10-Q for the period ended June 30, 2023, the definition of Adjusted EBITDA is the same as the definition of Consolidated EBITDA in the Credit Agreement.
Rest of the answer

The amounts presented below for

Consolidated EBITDA are the same as the amounts presented as Adjusted EBITDA on pages 72 and 74 of the Forms 10-K for periods ended December 31, 2021 and 2022, respectively, and pages 42 and 44 of the

Forms 10-Q for the three-month periods ended March 31 and June 30, 2023, respectively.

(in millions)

FY 2021

FY 2022

Q1 2023

Q2 2023

Total Consolidated Cash Royalty Receipts and Milestone Payment Receipts in respect of Royalty

Assets

(i)

$

2,608.5

3,231.3

1,223.0

637.1

Plus: Any other payments received in respect of Royalty Assets

(ii)

—

Plus: Any payments received in respect of strategic alliances, life sciences research agreements or other similar arrangements

(iii)

Plus: Net cash amount of any payments received and made in such period in respect of Swap

Agreements entered into for the purpose of hedging foreign exchange risk

(iv)

Less: Total consolidated cash operating payments

(v)

(184.5

)

(223.0

(86.8

(47.0

Less: Amounts included in the preceding clauses (i), (ii), (iii), or (iv) paid or distributed to non-controlling interests

(vi)

(479.6

(442.0

(91.9

(92.5

Read in the reply
In its next report

First report after the company's reply of Sep 19, 2023: 10-Q filed Nov 8, 2023 ↗, against the 10-Q filed May 9, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Non-GAAP Financial Results, page 68
SEC asked (2)
With regards to each of your reconciliations provided on page 74, please address the following: • Explain the apparent inconsistencies with regards to certain reconciling items in your non-GAAP measures. For example, we note that you present proceeds from available for sale debt securities as a reconciling item however you do not include purchases of available for sale debt securities in the reconciliation.
Rest of the question

• In addition, certain adjustments to these non-GAAP liquidity measures appear to be inconsistent with Item 10(e)(1)(ii)(A) of Regulation S-K. Please advise. • With regards to your non-GAAP measure, Adjusted Cash Flow, please more clearly explain what this measure represents and how you determined its presentation complies with Item 10(e)(1)(i)(C) of Regulation S-K.

RPRX answered
to prior comment two acknowledges that the reconciliations from Net cash from operating activities to Adjusted EBITDA and Adjusted Cash Receipts add back certain “charges or liabilities that required, or will require, cash settlement” which is prohibited by Item 10(e)(1)(ii)(A) of Regulation

S-K. Please further explain to us how you determined that your current presentation depicting such adjustments is appropriate.
Rest of the answer

As part of your response, tell us how you considered the response to Question

102.09 of the non-GAAP Compliance and Disclosure Interpretations which states that when a Credit Agreement contains a material covenant regarding a non-GAAP measure,

“the Company may be required to disclose the measure as calculated by the debt covenant as part of its MD&A.”

Your response to prior comment two further states that your Adjusted Cash Flow measure provides meaningful information about your ability to successfully operate your business and generate cash flow. Please explain in detail how the adjustments made to calculate the Adjusted Cash Flow measure result in a measure that meets this stated purpose. As part of your response, specifically address the apparent inconsistencies in that certain cash outflows are excluded from the measure when the corresponding cash inflows are included in the measure, as noted in our prior comment.

Response:

Background

The Company respectfully acknowledges the Staff’s comment and would like to offer the Staff additional background on the Company’s unique business model, which the Company believes is important for understanding its non-GAAP metrics and their materiality to investors.

As the Company noted in response to the

Staff’s June 28, 2023 letter, the Company’s business model is different from that of traditional operating companies in the biopharmaceutical industry. In summary, the Company acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations, inventors and life sciences companies) for a cash payment in exchange for future cash royalty payments made by the marketers of the products. In addition, the Company collaborates with life sciences companies to fund late-stage human clinical trials in exchange for future royalty payments if the products ultimately receive regulatory approval and generate commercial sales. The Company’s business and performance is dependent on its ability to deploy capital to acquire new royalties and the future cash inflows it receives from those royalty investments. Unlike conventional biopharma companies, the Company does not engage in the discovery, development, manufacturing or marketing of biopharmaceutical products. As a result, the Company believes that its investors and research analysts rely on the cash fundamentals of its business – specifically, the Company’s ability to generate cash from investments and use that cash to make future investments or to engage in other capital transactions such as dividends, share repurchases and debt service – when assessing the business.

Each quarter, the Company collects cash receipts from royalty investments, pays cash expenses, makes debt service payments, returns capital to shareholders in the form of dividends and share repurchases, and then reinvests the overwhelming majority of the cash it generates to make new royalty investments with the goal of growing, diversifying and extending the duration of the

Company’s royalty portfolio while generating an attractive rate of return on the capital it deploys. Because the Company’s most significant use of cash receipts from royalty investments is making new royalty investments, the Company believes its investors and research analysts are keenly focused on changes in the Company’s capacity to make new investments based upon (a) cash generated by the Company on its existing royalty investments and (b) projected future cash returns on its existing royalty investments.

As disclosed in the Company’s Form 10-K, most of the Company’s royalties are classified as financial assets that are measured at amortized cost using the effective interest method. As a result, the Company’s GAAP results of operations can be volatile and unpredictable.1 In addition, the Company believes there is no direct correlation between income from its royalties and cash royalty receipts due to the effective interest method. As discussed with the Staff during the September 5, 2023 teleconference with the Company, a number of Wall Street research analysts have highlighted the challenges of evaluating the quarterly cash generated by the Company’s royalty portfolio based on the Company’s GAAP income statement. These comments are highlighted on slides 3 and 4 of the slide deck that was provided via separate email (the “Analyst Slide Deck”).

The Company recognizes the challenge faced by investors and research analysts in interpreting its income statement and in an effort to compensate for this issue, the Company uses the direct method to prepare its Statements of Cash Flows and prioritizes transparent disclosure of its cash royalty receipts, including Adjusted Cash Receipts, to provide a more comprehensive presentation of the Company’s sources of capital for future investment. As also discussed during the September 5 teleconference and shown on slide 5 of the Analyst Slide Deck, six of the seven Wall Street research analysts who currently follow the

Company and publish research reports do not include a GAAP income statement forecast in their published research reports, while all seven of these research analysts provide detailed forecasts for Adjusted Cash Receipts, Adjusted EBITDA and Adjusted

Cash Flow. The Company respectfully advises the Staff that it believes that this supports its view that the Company’s shareholders are attracted to the cash fundamentals of the Company’s business.

As a result of the challenges investors and research analysts face in interpreting its GAAP income statement, the Company uses non-GAAP financial measures to supplement investors’ understandings of the Company’s ability to generate cash that can be used to make future investments or to engage in other capital transactions. The basis for each of these non-GAAP financial measures is discussed in greater detail below.

Adjusted EBITDA

In response to the Staff’s comment in the first bullet of Comment 2 with respect to Adjusted EBITDA, the Company respectfully advises the Staff that it believes its presentation of Adjusted EBITDA, including adjustments to add back certain

“charges or liabilities that required, or will require, cash settlement,” is appropriate and follows the guidance set forth in Question 102.09 of the Compliance and Disclosure Interpretations regarding

Non-GAAP Financial Measures (“Question 102.09”).

As discussed on page 53 of the Company’s Form 10-K, declines in sell-side equity research analysts’ consensus sales forecasts over a long time horizon can result in an immediate non-cash income statement expense recognition, even though the applicable cash inflows will not be realized for many years into the future. For example, in late 2014, the Company acquired a royalty on the cystic fibrosis franchise and shortly after, declines in near-term sales forecasts of sell-side equity research analysts resulted in recognition of non-cash provision expense in its consolidated income statements. Over the course of 10 quarters, the Company continued to recognize non-cash provision expense due to changes in sales forecasts, ultimately reaching a peak cumulative allowance of $1.30 billion in 2017. Following the approval of the Vertex triple combination therapy, Trikafta, in October 2019, sell-side equity research analysts’ consensus sales forecasts increased to reflect the larger addressable market and the extension of the expected duration of the Trikafta royalty, resulting in the reversal of the remaining $1.10 billion cumulative allowance. The recognition of the associated non-cash provision income of $1.10 billion in 2019 was not tied to royalty receipts, but rather to the increase in sales forecasts. This example illustrates the volatility caused by the Company’s accounting model in its consolidated income statements.

The Company’s calculation of Adjusted EBITDA is in strict compliance with the Credit

Agreement’s definition of Consolidated EBITDA. The Company’s calculation of Adjusted EBITDA does add back cash settled charges related to interest and development-stage funding payments, but that is what is required by the Credit

Agreement’s definition of Consolidated EBITDA.

The Company considered the requirement under Question 102.09 to “disclose the measure as calculated by the debt covenant as part of its MD&A” by disclosing the components of Adjusted EBITDA (which is defined in the Company’s Credit Agreement as Consolidated EBITDA).

The Company notes that on page 43 of its Form 10-Q for the period ended June 30, 2023, it disclosed that the definition of Adjusted EBITDA is the same as the definition of Consolidated EBITDA in the Credit Agreement, and that the covenants in the Credit Agreement related to Consolidated EBITDA are material terms of the Credit Agreement and material to an investor’s understanding of the Company’s liquidity. As further contemplated by Question 102.09, on page 119 of the Company’s Form 10-K, the Company disclosed the material terms of the Consolidated EBITDA-related covenants, the amounts required for compliance with the Consolidated EBITDA-related covenants, and the effects of non-compliance with the covenants in the Credit

Agreement.

Adjusted Cash Receipts

In response to the Staff’s comment in the first bullet of Comment 2 with respect to Adjusted Cash Receipts, the Company respectfully advises the Staff that it believes that its presentation of Adjusted Cash Receipts follows the guidance set forth Question 102.09 for two reasons:

Adjusted Cash Receipts is a key input for the calculation of Adjusted EBITDA.

As noted above in response to Comment 1, Adjusted EBITDA is total cash royalty receipts less total distributions to legacy non-controlling interests and total operating payments.

As disclosed in the Company’s Form 10-K, “legacy non-controlling interests” holders are entitled to a contractual percentage of the Company’s cash royalty receipts. Adjusted Cash Receipts is equal to total cash royalty receipts less the cash flow attributable to these legacy non-controlling interests. Adjusted Cash Receipts, therefore, represents the cash royalty receipts owned by the Company and its continuing investors.

Adjusted Cash Receipts is also a key input for calculating the largest component of total operating payments, which is the management fee payable to the Company’s external manager (the largest component of which is 6.5% of Adjusted Cash Receipts).

The Company, therefore, believes that reporting Adjusted Cash Receipts is critical to enable investors and research analysts to calculate Adjusted EBITDA.

The Company believes that Adjusted Cash Receipts are material to investors’ and research analysts’ understanding of the cash inflows from its royalty portfolio that enable the Company to make future investments. As discussed during the September 5 teleconference and as highlighted on slides 7-9 of the

Analyst Slide Deck, all of the eight independent research analysts who currently follow the Company track and forecast Adjusted Cash Receipts. These independent research analysts (a) use Adjusted Cash Receipts as a measure of the cash inflows of the Company during a period and (b) forecast Adjusted Cash Receipts (applying disclosed royalty rates to product sales forecasts) as a measure of the Company’s capacity to make additional investments or engage in capital transactions such as dividends, share repurchases and debt prepayments. As discussed during the September 5 teleconference and as shown in slides 10-18 of the Analyst Slide Deck, the Company believes that these research analysts forecast Adjusted Cash Receipts because of the difficulty of forecasting the Company’s ability to make future investments based on its GAAP income statement.

Adjusted Cash Flow response to the Staff’s comment in the second bullet of Comment 2 regarding Adjusted Cash Flow, the Company respectfully advises the Staff that Adjusted Cash Flow represents the net cash generated by the business each period, after cash expenses, that is available to fund future royalty investments or engage in capital transactions such as dividends, share repurchases and debt prepayments. The components of Adjusted Cash Flow that are not included in Adjusted EBITDA are net cash interest expense, upfront and ongoing development-stage funding payments (including investments in equity method investees (which the Company and its lenders consider to be similar to development-stage funding)) and contributions from legacy non-controlling interests. Adjusted Cash Flow measures the Company’s cash resources available to be redeployed into new royalty investments or engage in capital transactions.

The Company occasionally provides funding to counterparties in the form of launch and development capital, which is reflected as available for sale debt securities on the Company’s consolidated balance sheets. In these investments, the Company makes an upfront payment in exchange for a series of long duration, fixed quarterly payments. Cash inflows and outflows for available for sale debt securities are included in the investing section of our Statements of Cash Flows.

Since the Company uses Net cash flow provided by operating activities as the most directly comparable GAAP measure to reconcile Adjusted Cash Flow, and Net cash flow provided by operating activities excludes cash inflows from available for sale debt securities, the

Company adds back these cash inflows since they provide consistent inflows that are viewed by the Company as fundamental to its business strategy.

The Company does not, however, make an adjustment to include the related outflows because the outflows are discretionary investments, which are excluded from Net cash flow provided by operating activities. Including discretionary purchases of available for sale debt securities in Adjusted Cash Flow would net the cash available to reinvest in the business (or distribute) against cash outflows from discretionary investments. The Company believes combining inflows and outflows in this manner would not be helpful to investors’ and research analysts’ understanding of the cash that the Company has available for investment in new royalties or for other capital transactions.2

In calculating Adjusted Cash Flow, launch and development capital is the only case where the Company includes cash inflows from the investing section without the corresponding cash outflows.

If you have any additional questions or comments, please do not hesitate to contact me at [email protected] or (212) 883-2276.

Read in the reply
In its next report

First report after the company's reply of Sep 19, 2023: 10-Q filed Nov 8, 2023 ↗, against the 10-Q filed May 9, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

SEC letter of Aug 8, 2023 ↗ no reply letter on EDGAR
Non-GAAP Financial Results, page 68
SEC asked (1)
We note your response to comment one of our letter dated June 28, 2023 includes language from your Credit Agreement regarding Consolidated EBITDA. We also note the disclosure on pages 68-69 of your Form 10-K regarding the definition of Adjusted EBITDA under your Credit Agreement.
Rest of the question

For each of the most recent two years and subsequent interim period, please provide us with a tabular breakdown of the calculation of your Adjusted EBITDA measure as it is defined in the credit agreement, separately quantifying each of the individual components identified in such definition.

RPRX answered

No reply letter found.

In its next report

First report after the SEC's letter of Aug 8, 2023: 10-Q filed Nov 8, 2023 ↗, against the 10-Q filed May 9, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Non-GAAP Financial Results, page 68
SEC asked (2)
Please address the following regarding your response to comment two of our letter dated June 28, 2023: • Your response to prior comment two acknowledges that the reconciliations from Net cash from operating activities to Adjusted EBITDA and Adjusted Cash Receipts add back certain “charges or liabilities that required, or will require, cash settlement” which is prohibited by Item 10(e)(1)(ii)(A) of Regulation S-K.
Rest of the question

Please further explain to us how you determined that your current presentation depicting such adjustments is appropriate. As part of your response, tell us how you considered the response to Question 102.09 of the non-GAAP Compliance and Disclosure Interpretations which states that when a credit agreement contains a material covenant regarding a non-GAAP measure, "the company may be required to disclose the measure as calculated by the debt covenant as part of its MD&A." • Your response to prior comment two further states that your Adjusted Cash Flow measure provides meaningful information about your ability to successfully operate your business and generate cash flow. Please explain in detail how the adjustments made to calculate the Adjusted Cash Flow measure result in a measure that meets this stated purpose. As part of your response, specifically address the apparent inconsistencies in that certain cash outflows are excluded from the measure when the corresponding cash inflows are included in the measure, as noted in our prior comment.

RPRX answered

No reply letter found.

In its next report

First report after the SEC's letter of Aug 8, 2023: 10-Q filed Nov 8, 2023 ↗, against the 10-Q filed May 9, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Non-GAAP Financial Results, page 68
SEC asked (1)
We continue to have concerns about your current presentation of Adjusted EBITDA. With regards to compliance with your credit agreement, you may disclose Adjusted EBITDA based on the calculation provided in your response to comment one in your letter dated September 19, 2023, which uses the same terminology used in the credit agreement and is calculated to reflect its definition in the credit agreement.
Rest of the question

Refer to question 102.09 of the non-GAAP Compliance and Disclosure Interpretations.

RPRX answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff that it will revise its disclosure in future filings, including its Annual Report on Form 10-K for the year ended December 31, 2023

(the “2023 10-K”), to present Adjusted EBITDA using the same terminology used in the Company’s credit agreement and calculated to reflect its definition in the credit agreement.
Rest of the answer

The Company further assures the Staff that any such disclosure will include the material terms of the Company’s credit agreement, the amount or limit required for compliance with the financial covenants that use Adjusted EBITDA and the actual or reasonably likely effects of compliance or non-compliance with the financial covenants that use Adjusted EBITDA on the Company’s financial condition and liquidity in accordance with Question 102.09 of the

Compliance & Disclosure Interpretations regarding Non-GAAP Financial Measures.

Read in the reply
In its next report

First report after the company's reply of Dec 11, 2023: 10-K filed Feb 15, 2024 ↗, against the 10-K filed Feb 15, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Non-GAAP Financial Results, page 68
SEC asked (2)
As noted in prior comment two, your presentation of Adjusted Cash Receipts as a non- GAAP measure appears to include certain adjustments that are prohibited by Item 10(e)(1)(ii)(A) of Regulation S-K. Please revise to remove your disclosure of Adjusted Cash Receipts as a non-GAAP measure.
RPRX answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff that it will revise its disclosure in its future filings, including its 2023 10-K, to remove its disclosure of Adjusted Cash Receipts as a non-GAAP measure. Management has concluded that it will refer to what was formerly known as “Adjusted Cash Receipts” as “Portfolio Receipts.” Portfolio receipts is a metric defined as the sum of (i) royalty receipts, which includes variable payments based on sales of products and (ii) milestones and other contractual receipts, which include sales-based or regulatory milestones
Rest of the answer

payments and other fixed contractual receipts, in each case net of contractual payments to the legacy non-controlling interests.

Management believes that Portfolio Receipts is a key performance metric because it represents the Company’s ability to generate cash from its portfolio investments, the primary source of capital that the Company can deploy to make new portfolio investments.

The table below reflects the new presentation of Portfolio Receipts that the Company will adopt in its 2023 10-K.

(in 000s)

Year Ended December 31,

Change

2022

2021

$

%

Cystic fibrosis franchise

690,007

582,378

107,629

18.5

Tysabri

304,794

304,264

530

0.2

Imbruvica

257,729

290,880

(33,151

)

(11.4

Xtandi

153,884

130,313

23,571

18.1

Promacta

149,707

143,104

6,603

4.6

Tremfya

97,307

35,718

61,589

172.4

Trelegy

89,915

—

Cabometyx/Cometriq

55,426

33,722

21,704

64.4

Evrysdi

40,645

16,098

24,547

152.5

Prevymis

37,126

37,505

(379

(1.0

Farxiga/Onglyza

36,134

29,984

6,150

20.5

Orladeyo

21,801

6,740

15,061

223.5

Trodelvy

20,448

11,041

9,407

85.2

Erleada

17,620

11,726

5,894

50.3

Crysvita

16,816

13,798

3,018

21.9

Emgality

15,522

12,760

2,762

21.6

Nurtec ODT

14,984

6,553

8,431

128.7

Other Product Royalties (1)

223,554

341,721

(118,167

(34.6

Royalty Receipts

2,243,419

2,008,305

235,114

11.7

Milestones and Other Contractual Receipts (2)

545,874

120,633

425,241

352.5

Portfolio Receipts

2,789,293

2,128,938

660,355

31.0

(1)

Other Product Royalties primarily include royalties on sales of the following products: Cimzia, Entyvio, HIV

Franchise, IDHIFA, Januvia, Janumet, Other DPP-IVs, Letairis, Lexiscan, Mircera, Myozyme, Nesina, Soliqua and Tazverik.

(2)

Milestones and Other Contractual Receipts include receipts related to Bosulif (a product co-developed by our joint venture investee, Avillion) and distributions from the Legacy SLP Interest, both of which are presented as Distributions from equity method investees on the Statements of Cash Flows).

Milestones and Other Contractual Receipts also include quarterly redemption payments of $12.9 million related to the Series A Biohaven Preferred Shares. The 2022 amount also includes accelerated redemption payments of $457.6 million for all outstanding Series A and Series B Biohaven Preferred Shares following Pfizer’s acquisition of Biohaven in October 2022. The 2021 amount also includes a one-time milestone payment of

$37.1 million that we received in respect of Soliqua.

The Company’s disclosures of this key performance metric will comply with the disclosure requirements in SEC Release No. 33-10751, including to disclose that Portfolio Receipts is a summation of the following line items from the Company’s Statement of Cash Flows :

•

Cash collections from financial royalty assets;

Cash collections from intangible royalty assets;

Other royalty cash collections;

Proceeds from available for sale debt securities; and

Distributions from equity method investees, less

Distributions to legacy non-controlling interests.

Portfolio Receipts does not include proceeds from equity securities or proceeds from purchases and sales of marketable securities, both of which the Company believes are not fundamental to its business strategy.

Read in the reply
In its next report

First report after the company's reply of Dec 11, 2023: 10-K filed Feb 15, 2024 ↗, against the 10-K filed Feb 15, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Non-GAAP Financial Results, page 68
SEC asked (3)
We have reviewed your response to prior comment two regarding the non-GAAP measure Adjusted Cash Flow. As the basis used to determine what amounts are included in and excluded from Adjusted Cash Flow remains unclear, please provide us with additional information explaining the manner in which this measure is calculated.
Rest of the question

In addition, further explain why this measure provides useful information to investors, including as compared to other disclosed amounts such as Net Cash Provided by Operating Activities. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

RPRX answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff that it will no longer report the non-GAAP measure Adjusted Cash Flow starting with the Company’s 2023 10-K. The Company respectfully advises the Staff that the Company intends to disclose two new non-GAAP measures, Portfolio Cash Flow and Portfolio Cash Flow After Capital Deployment.1

As noted in prior correspondence with the Staff, the Company believes its investors and research analysts rely on the cash fundamentals of its business — specifically, the Company’s ability to generate cash from portfolio
Rest of the answer

investments and use that cash to make future portfolio investments or to engage in other capital transactions such as dividends, share repurchases and debt service — when assessing the business. Portfolio Cash Flow will present cash generated from portfolio investments after cash payments for operating and professional costs and interest, and Portfolio Cash Flow After Capital Deployment will present cash generated from portfolio investments after cash payments for operating and professional costs and interest, and all investments in royalties, milestones and other contractual receipts. We will supplementally present the detail of capital deployment by category as they appear on the Company’s GAAP financial statements. Capital Deployment represents the total outflows that will drive future Portfolio Receipts as outlined in the above Question 2 response. Capital

Deployment does not include investments in equity securities or marketable securities for the reasons noted in the above Question 2 response.

For clarity, the Company will comply with Item 10(e)(1(ii)(A) of Regulation

S-K when disclosing Portfolio Cash Flow and Portfolio Cash Flow After Capital Deployment. Portfolio Cash Flow will exclude cash settled charges in the form of development-stage funding payments, however,

Portfolio Cash Flow (and Portfolio Cash Flow After Capital Deployment) will not be included in periodic reports filed with the Commission, including the Company’s Annual Reports on Form 10-K.

These two new measures, Portfolio Cash Flow and Portfolio Cash Flow After Capital

Deployment, will simplify the presentation of the Company’s cash fundamentals to investors. Portfolio Cash Flow will include all cash generated by portfolio investments less cash payments for operating and professional costs and interest. Similarly, Portfolio Cash Flow After Capital Deployment will account for all cash used in the Company’s business of making portfolio investments that will generate future Portfolio Receipts, regardless of how such investment is classified in the Company’s Statement of Cash Flows2.

Portfolio

Cash Flow will provide investors with a single measure of the cash generated by the Company’s fundamental investment business each period, after cash expenses that are necessary to operate the business, and that is, therefore, available to fund future portfolio investments (i.e., generate future Portfolio Receipts) or engage in capital transactions. Portfolio Cash Flow After Capital Deployment will provide investors with a single measure of the cash generated or expended by the business each period after capital deployment for portfolio investments during a period.

The Company will reconcile Portfolio Cash

Flow and Portfolio Cash Flow After Capital Deployment to Net cash provided by operating activities. While not a replacement for GAAP, the Company believes this supplemental information is useful to investors because under GAAP, cash generated by (used in) the Company’s portfolio investments is presented in various line items of its Statement of Cash Flows in a manner that makes it difficult to easily understand the cash fundamentals of its business. Management has concluded that

Portfolio Cash Flow and Portfolio Cash Flow After Capital Deployment provide valuable information to investors about the net cash inflows of the business before and after capital deployment for portfolio investments.

* * *

We hope that the foregoing has been responsive to the Staff’s comments. Please do not hesitate to contact me by telephone at (212) 883-2276 or via e-mail at [email protected] with any questions or comments regarding this correspondence.

Read in the reply
In its next report

First report after the company's reply of Dec 11, 2023: 10-K filed Feb 15, 2024 ↗, against the 10-K filed Feb 15, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: company letter, Jul 13, 2023, closing letter, 2024-01-30

Form S-1

2020-03-12 to 2020-06-11 · 66 questions · 4 letters from the SEC, 1 from the company
No closing letter
Risk factorsResults discussion (MD&A)Liquidity and cashRevenueNon-GAAP measuresDebtAcquisitionsGoodwill and impairmentIncome taxesLegal and contingenciesExecutive pay
SEC letter of Mar 12, 2020 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Draft Registration Statement on Form S-1 submitted February 13, 2020 · Our Portfolio, page 4
SEC asked (1)
For each of the commercial products and product candidates shown in your table, please expand the table to include a brief indication of how you have invested in these products or product candidates. In this regard, we note your disclosure under "Acquisition of royalties" on page 101 of the classifications of the various structures through which you acquire the rights to royalties.
Rest of the question

Please advise us if those classifications would be the most useful way to present the requested information to investors in this section.

RPRX answered

No reply letter found.

Draft Registration Statement on Form S-1 submitted February 13, 2020 · Our Portfolio, page 4
SEC asked (2)
Please revise the table to remove the estimated "Total End Market Sales" figures for each third-party drug or explain why you believe it is appropriate to highlight prominently these figures in the table. Also, tell us your basis for highlighting a single year of royalty receipts by discussing whether this information provides investors with an adequate basis to assess the significance of each royalty right.
RPRX answered

No reply letter found.

Draft Registration Statement on Form S-1 submitted February 13, 2020 · Our Portfolio, page 4
SEC asked (3)
For each product, disclose the expected duration of the royalty obligations to which you are entitled, including, where appropriate, by disclosing the expiration dates of the underlying patents or projected expiration dates for any patents that may issue from pending applications.
Rest of the question

If patent cliffs will materially impact your royalty receipts in the next few years, then please revise the table to prominently disclose this information and discuss such cliffs in other sections of the prospectus, where appropriate. Our portfolio is highly diversified across products, therapeutic areas and marketers, page 5

RPRX answered

No reply letter found.

Draft Registration Statement on Form S-1 submitted February 13, 2020 · Our Portfolio, page 4
SEC asked (4)
We refer to your risk factor disclosure on page 25 concerning your reliance on a limited number of products. Please balance your prospectus summary disclosure concerning your high degree of product diversification by also addressing your reliance on a limited number of products.
RPRX answered

No reply letter found.

The Manager, page 9
SEC asked (5)
Please revise to identify the Manager and discuss the relationship between the Manager and your officers and directors. Also, briefly indicate the formula for determining how the fixed fee payable to the Manager on Adjusted Cash Receipts, and the fixed fee payable to the Manager on "certain assets," will be determined.
Rest of the question

Similarly, briefly indicate the formula for determining how the quarterly dividends payable to Equity Performance Award Holdings, an affiliate of the Manager, will be determined.

RPRX answered

No reply letter found.

The Reoganization Transactions, page 9
SEC asked (6)
Please revise your diagram on page 10 and on page 53 to show that the Manager will be entitled to Operating and Personnel Payments, to Equity Performance Awards and to dividends through its ownership interests of RPI GP 2019, LP.
RPRX answered

No reply letter found.

The Reoganization Transactions, page 9
SEC asked (7)
Given the information in your diagram on page 10 that you will be entitled to 82% of the Existing Royalties and 100% of the New Royalties, please make it more clear in your disclosure that investors in your offering will be making an investment decision based on a royalty stream that is more heavily weighted towards New Royalties as compared to your legacy investors.
Rest of the question

Please also tell us if these arrangements present any additional risk factors, or conflicts of interests, that should be disclosed to investors in your offering.

RPRX answered

No reply letter found.

Summary of the Offering Structure, page 11
SEC asked (8)
We note your disclosure that your offering is being conducted through an "Up-C" structure. Please tell us whether you are entering into any tax receivable agreements as part of the reorganization.
RPRX answered

No reply letter found.

Risk Factors, page 12
SEC asked (9)
With reference to your disclosures on pages 47 and 169, please revise the summary to highlight your anticipated PFIC status and risks to U.S. holders if they do not file timely a QEF election and/or fail to file annual information returns on IRS Form 8621. Risk Factors, page 21
RPRX answered

No reply letter found.

Risk Factors, page 12
SEC asked (10)
Although we note your disclosure in the seventh bullet point under "Risk Factors" on page 12, we see limited risk factors addressing actual and potential conflicts of interest with the Manager and its affiliates. In this regard, we note your disclosure under "Conflicts of Interest" on page 144 regarding Mr.
Rest of the question

Legorreta's involvement with BioPharma Credit PLC and the potential for conflicts of interest described in that section. Please ensure that your risk factors address all material actual and potential conflicts of interest. We have no employees and will be entirely dependent upon the Manager for all the services we require, page 23

RPRX answered

No reply letter found.

Risk Factors, page 12
SEC asked (11)
We note from your disclosure under "The Manager" on page 134 that you will retain the right to remove the Manager in "certain circumstances." If your ability to remove the Manager is limited, please expand this risk factor as appropriate. We make assumptions regarding the royalty duration for terms that are not contractually fixed...,
RPRX answered

No reply letter found.

Risk Factors, page 12
SEC asked (12)
Please revise to clarify the risk by indicating whether a shortened royalty term has caused a permanent impairment in recent years.
RPRX answered

No reply letter found.

The success of our business depends upon key members of the Manager's senior advisory team..., page 35
SEC asked (13)
We note your disclosure on page 144 that Mr. Legorreta is a co-founder of, and has significant influence over, Pharmakon Advisors. Given this position, please expand your risk factor disclosure, if appropriate, to discuss any material constraints on the time that Mr. Legorreta has to devote to you and/or the Manager.
Rest of the question

If our Class A ordinary shares are not eligible for deposit and clearing within the facilities of DTC..., page 45

RPRX answered

No reply letter found.

The success of our business depends upon key members of the Manager's senior advisory team..., page 35
SEC asked (14)
Please tell us, and revise as applicable to clarify, whether this risk applies to all publicly traded companies or whether the risk is more pronounced for public companies incorporated in the U.K. Also, clarify whether your shares could continue to be listed on the NYSE or Nasdaq in the event that DTC ceased to act as a depositary and clearing agency for your ordinary shares.
RPRX answered

No reply letter found.

We expect to be treated as a PFIC for U.S. federal income tax purposes..., page 47
SEC asked (15)
We note your disclosure that you "expect to provide information to all electing shareholders needed to comply with the QEF election, including with respect to any of [y]our subsidiaries that may be classified as a PFIC" and that "no assurance can be given that [you] will be able to provide information necessary to make QEF elections with respect to any subsidiary that is a PFIC and that you will not control." Please
Rest of the question

disclose any material adverse consequences to your shareholders if you are not able to provide the information necessary for them to make QEF elections with respect to any subsidiary that is a PFIC and that you do not control.

RPRX answered

No reply letter found.

Unaudited Pro Forma Financial Information, page 62
SEC asked (16)
Please note that once you have included complete pro forma financial information in your Form S-1, we will need sufficient time to review such information and may have additional comments based on your compliance with Article 11 of Regulation S-X.
Rest of the question

We also encourage you to present your pro forma adjustments in separate columns to more clearly illustrate the impacts of the various transactions (e.g., Exchange Offer Transactions, Reorganization Transactions, sale of Class A ordinary shares in IPO, etc. ) to which you are giving effect.

RPRX answered

No reply letter found.

Management's Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked (17)
Please describe material known trends or uncertainties that have had, or that you reasonably expect will have, a material favorable or unfavorable impact on total income and revenues or results of operations. For example, if the Operating and Personnel Payments under the new Management Agreement or other aspects of the Exchange Offer Transactions and Reorganization Transactions will materially impact your general
Rest of the question

and administrative expenses or your total operating expenses, or impact your operating income, please include appropriate disclosure. Please also disclose any known funding commitments that would be material to an understanding of your operating results and financial condition.

RPRX answered

No reply letter found.

Understanding Our Results of Operations, page 84
SEC asked (18)
Please quantify the term "de minimis" in paragraph 4 and tell us why it would not be appropriate to reflect this interest in your organizational diagram on pages 10 and 53. Income from royalty assets, page 89
RPRX answered

No reply letter found.

Understanding Our Results of Operations, page 84
SEC asked (19)
You provide an overview of your royalty portfolio on page 83 which disaggregates both your growth and mature product royalties by product and quantifies the royalties received from each. Please consider providing a similar presentation for your income from royalty assets in order to more clearly illustrate the underlying changes in this income from period to period.
Rest of the question

In this regard, consider disaggregating your royalty income by product for each period along with the corresponding yield for that period.

RPRX answered

No reply letter found.

Income from royalty assets — Years ended December 31, 2018 and 2017, page 90
SEC asked (20)
Please quantify the increases and the offsets for the product categories described in the second sentence of the first paragraph of this section.
RPRX answered

No reply letter found.

Provision for changes in expected cash flows from royalty assets, page 91
SEC asked (21)
Please revise your discussion of changes in your provision to address the credits recorded to the provision related to your cystic fibrosis franchise in both 2018 and 2017 as well as for Letairis in 2018.
RPRX answered

No reply letter found.

Non-GAAP Financial Results, page 93
SEC asked (22)
So that you do not give undue prominence to your discussion of non-GAAP measures, please revise your discussion of your Results of Operations beginning on page 89 to incorporate your discussion on pages 95-97 regarding each of your products to the extent that this information also impacts the amount of royalty income and revenues recognized in your financial statements for each period.
RPRX answered

No reply letter found.

Commitments, Contingencies and Guarantees, page 102
SEC asked (23)
Please revise footnote 3 to your table in this section to clarify, if true, that the table excludes the Operating and Personnel Payments payable under the new Management Agreement. If Operating and Personnel Payments will be payable under the New Management Agreement, as described in footnote 3, during the "2022-2023" and "Thereafter" periods, please revise the table to indicate the potential for such payments
Rest of the question

rather than indicating "N/A" in the table for those periods.

RPRX answered

No reply letter found.

Credit and Counterparty Risk, page 106
SEC asked (24)
Although we note your reference to the Company Overview within your MD&A for a discussion of your concentration of receivables balances with select marketers, we do not see this disclosure in your filing at this time. Please advise.
RPRX answered

No reply letter found.

Financial Covenants, page 107
SEC asked (25)
We note your disclosure in the first paragraph of this section that the Credit Agreement contains financial covenants that require you to maintain compliance with specified financial ratios. Although we note your disclosure regarding Adjusted EBITDA and your Secured Leverage ratio in the next paragraph, please revise future amendments to disclose clearly whether you are and have been in compliance with the financial
Rest of the question

covenants specified in the first paragraph of this section.

RPRX answered

No reply letter found.

Senior Secured Credit Facilities, page 107
SEC asked (26)
Although we note your disclosure that the maturity dates and interest rates applicable to certain tranches of term loans under the Credit Agreement are described in "Long-term Debt," we do not see this disclosure in your filing at this time. Please advise.
Rest of the question

Also please advise whether you will update the "Borrowings" presentation included on page 101 to add the terms of the new Credit Agreement, and any balances as of March 31, 2020.

RPRX answered

No reply letter found.

Development-Stage Product Candidates, page 130
SEC asked (27)
Please revise the disclosure in this section to provide royalty rate disclosures applicable to the development-stage product candidates.
RPRX answered

No reply letter found.

U.S. Investment Company Act Status, page 135
SEC asked (28)
Please note we will continue to assess the disclosure in this section and in the risk factor on pages 34-35 and may have further comment.
RPRX answered

No reply letter found.

Management, page 137
SEC asked (29)
We note your disclosure in the last risk factor on page 23 that your success will be largely dependent upon the expertise and services of others, including the investment committee. Accordingly, please disclose who is serving or will be serving on the investment committee.
RPRX answered

No reply letter found.

Directors (who are not Executive Officers), page 138
SEC asked (30)
Refer to Regulation S-K Item 401(e)(1) and ensure that you have described the business experience during the past five years of each director and each person's principal occupations and employment during the past five years. As examples, please disclose: (i) when Dr. De Souza become the Executive Chairman of Bionomics Ltd.; (ii) whether Mr.
Rest of the question

Norden's position as Chief Financial Officer of Wyeth ended within the last five years; (iii) Mr. Giuliani's principal business occupations and employment during the past five years; and (iv) whether Mr. Riggs continues to serve on the Investment Committee.

RPRX answered

No reply letter found.

Executive Officer Compensation, page 142
SEC asked (31)
With reference to your disclosure at the bottom of page F-28, please provide us an analysis explaining why you do not include Regulation S-K, Item 402 disclosure for fiscal 2019. Please also provide us with additional analysis to support your position that Item 402 disclosure will not be required for future periods given your newly adopted structure.
RPRX answered

No reply letter found.

Certain Relationships and Related Party Transactions, page 144
SEC asked (32)
Please file the agreements related to the Equity Performance Awards and the Director Appointment Agreement as exhibits to your filing.
RPRX answered

No reply letter found.

Operating and Personnel Payment, page 145
SEC asked (33)
With respect to the 0.25% fee payable on the GAAP value of security investments at the end of the quarter, it appears that the Manager would be entitled to this fee based on the mark-to-market value of those securities at the end of every quarter even though you might not actually realize any gains in those securities when sold. If that is the case, please make that clear.
Rest of the question

If this fee structure presents a conflict of interest, please include appropriate disclosure, including risk factor disclosure.

RPRX answered

No reply letter found.

Equity Performance Awards, page 146
SEC asked (34)
We note that the Equity Performance Awards are based on a portfolio-by-portfolio basis and that investments made during each two-year period will be grouped together as a separate portfolio. Please disclose the business purpose for separating your investments into portfolios based on two-year periods for purposes of the Equity Performance Awards.
Rest of the question

Since investors in your Class A ordinary shares will have exposure to all of your investments, please expand your penultimate risk factor on page 35 to disclose any additional material risks to investors in your offering from the Equity Performance Awards being determined on a portfolio-by-portfolio basis, including that there may be Equity Performance Awards payable to your affiliates when your overall portfolio of investments is not performing as well as the portfolios used as the basis for measuring the Equity Performance Awards.

RPRX answered

No reply letter found.

Equity Performance Awards, page 146
SEC asked (35)
Since the Equity Performance Awards will be payable in RP Holdings Class B Interests that will be exchanged upon issuance for Class A ordinary shares, please disclose the potential for dilution to holders of the Class A ordinary shares as a result of the Equity Performance Awards.
Rest of the question

Please also disclose if there will be a potential range of such dilution on a yearly or other basis, or a maximum cap on the Equity Performance Awards, and include risk factor disclosure if appropriate.

RPRX answered

No reply letter found.

Review, Approval or Ratification of Transactions with Related Parties, page 149
SEC asked (36)
Please disclose the standards that will be applied in determining whether to approve any of the transactions described in this section. Refer to Item 404(b)(1)(ii) of Regulation S- K.
RPRX answered

No reply letter found.

Security Ownership of Certain Beneficial Owners and Management, page 151
SEC asked (37)
We note from footnote 1 to your table that beneficial ownership of the Class A ordinary shares reflects beneficial ownership of RP Holdings' Class B Interests exchangeable for Class A ordinary shares "immediately following the offering." Given the disclosure in the first sentence of footnote 1, which indicates that the exchanges of the Class B Interests for Class A ordinary shares may not occur until after the
Rest of the question

expiration of the underwriters’ lockup agreements, it is not clear from your current disclosure how the Class B Interests will be reflected in your beneficial ownership table. Please advise and revise your disclosure as necessary for clarity.

RPRX answered

No reply letter found.

Voting Rights, page 155
SEC asked (38)
Refer to to Regulation S-K Item 202(a)(1)(v) and specify the vote required by security holders to take action on ordinary resolutions.
RPRX answered

No reply letter found.

Annual Accounts and Independent Auditor, page 158
SEC asked (39)
We note your disclosure in the first paragraph on page 159 that annual accounts and reports must be presented to the shareholders at a general meeting prepared in accordance with IFRS as adopted by the European Union. If you will not also be providing such reports in U.S. GAAP, please revise your disclosure as appropriate.
RPRX answered

No reply letter found.

Class A Ordinary Shares Eligible for Future Sale, page 161
SEC asked (40)
We refer to your disclosure in the parenthetical of the first sentence of the third paragraph of this section and the similar disclosure in parenthetical of the second paragraph under "Lock-Up Arrangements" on page 162.
Rest of the question

Please tell us why the numbers or percentage in these parentheticals would change if the underwriters exercise their option to purchase additional shares in full and "after giving effect to the use of the net proceeds therefrom," or revise your disclosure as appropriate.

RPRX answered

No reply letter found.

U.K. taxation of dividends; and · U.K. taxation on capital gains, page 163
SEC asked (41)
We note your disclosure in these sections that U.S. holders, under the circumstances described, "should not" be subject to U.K. tax in respect of any dividends, "should not" be liable to U.K. capital gains tax, and "should not be" liable for U.K. corporation tax. Please unequivocally state what the tax consequences will be, not what they "should" or "should not" be.
Rest of the question

If you are unable to provide an unequivocal statement, for each material tax consequence where uncertainty exists, please disclose the reason for the uncertainty, the degree of the uncertainty, the possible alternatives, and the risks to investors, including appropriate prospectus summary and risk factor disclosure. For guidance, refer to Section III.C of Staff Legal Bulletin 19, Legality and Tax Opinions in Registered Offerings (October 14, 2011).

RPRX answered

No reply letter found.

Consolidated Balance Sheet, page F-3
SEC asked (42)
Please revise both your current and non-current line items "Royalty assets, net - financial assets" to parenthetically quantify the amount of the allowance for changes in expected cash flows.
RPRX answered

No reply letter found.

Consolidated Statements of Comprehensive Income, page F-4
SEC asked (43)
In order to more clearly understand and differentiate your revenue streams from royalty assets, please consider revising your revenue line items to indicate the specific royalty assets from which such revenues are derived. For example, consider labeling your revenue streams as "Income from financial royalty assets" and "Revenue from intangible royalty assets" or something similar.
Rest of the question

Notes to Consolidated Financial Statements 2. Summary of Significant Accounting Policies

RPRX answered

No reply letter found.

Royalty Assets, page F-9
SEC asked (44)
Please demonstrate how you determined that the accounting in ASC 310 - Receivables, is the appropriate accounting guidance to account for the "royalty assets, net - financial assets" applying the guidance to your specific facts and circumstances. In this regard, tell us whether there were any accounting alternatives that you considered. Investment in non-consolidated affiliates, page F-14
RPRX answered

No reply letter found.

Royalty Assets, page F-9
SEC asked (45)
For both of the Avillion entities in which you have made an investment, please provide us with your analysis supporting your conclusion that you do not have the power to direct the activities that most significantly influence the economic performance of the entity. Concentrations of credit risk, page F-15
RPRX answered

No reply letter found.

Royalty Assets, page F-9
SEC asked (46)
Please file your agreement with Vertex as an exhibit or provide us with an analysis supporting your determination that you are not substantially dependent on that agreement. 7. Cumulative Allowance for Changes in Expected Cash Flows from Royalty Assets, page F-22
RPRX answered

No reply letter found.

Royalty Assets, page F-9
SEC asked (47)
Please revise to present your allowance rollforward by product similar to the level of disaggregation in your royalty assets table on page F-21.
RPRX answered

No reply letter found.

Signatures, page II-4
SEC asked (48)
Please revise to indicate who is signing in the capacity of your principal financial officer and to include the signature of your authorized representative in the United States. Please refer to Instruction 1 to Signatures to Form S-1.
RPRX answered

No reply letter found.

General
SEC asked (49)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
RPRX answered

No reply letter found.

SEC letter of Apr 10, 2020 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
SEC asked (1)
With reference to prior comment 28, please provide us with a legal analysis of the impact of the company’s intent to be treated as a PFIC on the company’s status under the Investment Company Act.
RPRX answered

No reply letter found.

SEC asked (2)
We refer to your disclosure in the last sentence on page 34 indicating that your subsidiaries that are so engaged rely on Section 3(c)(5)(A) of the U.S. Investment Company Act, which, “as interpreted by the SEC staff, requires each such subsidiary to invest” at least 55% of its assets in notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of
Rest of the question

merchandise, insurance, and services. In order to conform with the staff's position, please revise this statement to clarify that “according to certain SEC staff interpretations," this provision "generally may be available to an issuer who invests” at least 55% of its assets in notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services. Please make any additional changes that would be required in order to conform to this characterization of the staff’s position. Ibrance, page 138

RPRX answered

No reply letter found.

SEC asked (3)
Please further revise your disclosure in response to prior comment 27 to disclose a royalty rate range for Ibrance and for PT027.
RPRX answered

No reply letter found.

Director and Executive Compensation, page 152
SEC asked (4)
Although we note you have disclosed on page 152 the Operating and Personnel Payments incurred during the year ended December 31, 2019, our prior comment 31 requested analysis explaining why you do not include Regulation S-K Item 402 disclosure for fiscal 2019.
Rest of the question

This would include an analysis of whether all plan and non-plan compensation awarded to, earned by, or paid to the named executive officers designated under paragraph (a)(3) of Item 402, and directors covered by paragraph (k) of Item 402, by any person for all services rendered in all capacities to the registrant and its subsidiaries, unless otherwise specifically excluded from disclosure in Item 402, should be disclosed. Please update us with your analysis in that regard and update your disclosure as appropriate. Please also provide us with additional analysis on your position as to whether such Item 402 disclosure would be required in filings for future periods.

RPRX answered

No reply letter found.

Security Ownership of Certain Beneficial Owners and Management, page 161
SEC asked (5)
Please revise to identify the natural persons with voting and/or dispositive control of the shares held by all entities listed in your tables on page 162.
RPRX answered

No reply letter found.

Capital Structure, page 164
SEC asked (6)
Please disclose the purpose of the Class R redeemable shares and disclose whether those shares will be redeemable at nominal value or otherwise.
RPRX answered

No reply letter found.

Signatures, page II-4
SEC asked (7)
Please refer to Instruction 1 to Signatures to Form S-1 and include the signature of your authorized representative in the United States, or advise.
RPRX answered

No reply letter found.

SEC letter of May 7, 2020 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Ibrance, page 137
SEC asked (1)
Your response to prior comment 3 indicates that disclosing royalty ranges for Ibrance and PT027 is not required because presentation of ranges for such immaterial assets would not be meaningful to investors in interpreting results or in assessing performance.
Rest of the question

Given your disclosure in the second paragraph of this section that global end market sales of Ibrance are expected to grow to approximately $9.4 billion in 2024, it is unclear from your current disclosure how investors would understand that royalties on Ibrance are immaterial to your business. Accordingly, please revise your disclosure to clarify the significance of the Ibrance assets. In addition, revise your presentation on page 4 so that you are not giving undue prominence to your Ibrance and PT027 assets by highlighting them in your Summary.

RPRX answered

No reply letter found.

Capital Structure, page 166
SEC asked (2)
Please disclose the substance of your response to prior comment 6.
RPRX answered

No reply letter found.

SEC asked (1)
Please revise your graphic to clarify the meaning of “2019A” end market sales. For example, please clarify if the “A” is intended to mean actual, approximate or something else. If these are estimated figures, or assumptions underlie the calculations, please discuss.
Rest of the question

In an appropriate location of your prospectus, indicate how these figures are useful to investors in understanding your royalty receipts and also how management uses them.

RPRX answered
The Company respectfully acknowledges the Staff’s comment, and, in response to the Staff’s comment, the Company has revised the graphic on page 4 and the disclosure on pages 4 and 131 of Amendment No. 3.
Read in the reply
SEC asked (2)
Please revise the prospectus to ensure that the disclosure of 2019A End Market sales in the graphics on page 4 reconcile to your disclosure regarding end market sales under “Our Portfolio” beginning on page 149, or advise.
Rest of the question

For example, we note your disclosure on page 151 indicates that total global end market sales for DPP-IV inhibitors during 2019 were approximately $10.7 billion whereas your disclosure on page 4 regarding Januvia, Janumet and other DPP-IV products indicates 2019A End Market Sales of $9.4 billion. Similarly, for Xtandi, your disclosure on page 149 indicates that total global end market sales for Xtandi during 2019 were approximately $4.3 billion whereas your disclosure on page 4 for Xtandi indicates 2019A End Market Sales of $3.5 billion.

RPRX answered
The Company respectfully acknowledges the Staff’s comment, and, in response to the Staff’s comment, the Company has revised the disclosure regarding end market sales on pages 151 and 152 Amendment No. 3.
Read in the reply
Summary of the Offering Structure, page 11
SEC asked (3)
Please tell us how your disclosure that your Class B shares will not entitle holders of those shares to receive distributions upon a liquidation, dissolution or winding up of the company reconciles to your disclosure under "Rights upon liquidation" on page 181 that the holders of Class B shares only have limited rights to receive a distribution equal to their nominal value upon a liquidation, dissolution or winding
Rest of the question

up of Royalty Pharma, following the prior payment of the nominal capital paid up or credited as paid up on each Class A ordinary share as well as an amount of $10,000,000 on each Class A ordinary share upon such liquidation, dissolution or winding up, or revise your disclosure as appropriate.

RPRX answered
The Company respectfully acknowledges the Staff’s comment, and, in response to the Staff’s comment, the Company has revised the disclosure on page 11 of Amendment No. 3.
Read in the reply
Footnotes to the Unaudited Pro Forma Consolidated Balance Sheet · Footnote G, page 71
SEC asked (4)
You disclose on page 9 that pursuant to agreements with the Continuing Investors Partnerships, that certain of the Continuing Investors have agreed to exchange interests in the Continuing Investor Partnerships into an aggregate of 290,833,447 Class A ordinary shares shortly before or upon consummation of this offering.
Rest of the question

This exchange, however, is not discussed in the notes to your Unaudited Pro Forma Consolidated Balance Sheet or in your Capitalization discussion on an as-adjusted basis on page 63. Please revise your disclosures in these sections to reflect the fact that your pro forma Class A ordinary shares as of March 31, 2020 include amounts issued in this exchange. Notes to the Condensed Consolidated Financial Statements 2. Summary of Significant Accounting Policies

RPRX answered
The Company respectfully acknowledges the Staff’s comment, and, in response to the Staff’s comment, the Company has revised the disclosure on pages 64, 72 and 75 Amendment No. 3.

Notes to the Condensed Consolidated Financial Statements

2. Summary of Significant Accounting Policies
Read in the reply
Recently adopted and issued accounting standards, page F-9
SEC asked (5)
You disclose that you recorded a cumulative adjustment to Retained earnings of $192.7 million to recognize an allowance for credit losses on your financial royalty assets as a result of the adoption of ASU 2016-13. Please revise to disclose the key changes to your allowance methodology as a result of this new guidance and how this adjustment was calculated.
Rest of the question

Please also update your accounting policy disclosure accordingly. Exhibits

RPRX answered
The Company respectfully acknowledges the Staff’s comment, and, in response to the Staff’s comment, the Company has revised the disclosure on page F-9 of Amendment No. 3.
Read in the reply
Recently adopted and issued accounting standards, page F-9
SEC asked (6)
The Exhibit 5.1 legality opinion should not assume conclusions of law that are necessary for the ultimate opinion. Please tell us why assumptions (8) and (9) on Schedule 2 of the of the legality opinion are appropriate or file a revised opinion.
RPRX answered
The Company respectfully acknowledges the Staff’s comment, and, in response to the Staff’s comment, a revised

Exhibit 5.1 legality opinion has been filed.
Read in the reply
Recently adopted and issued accounting standards, page F-9
SEC asked (7)
Based on the list of documents examined by counsel in Schedule 1 of the Exhibit 5.1 opinion, it does not appear that counsel reviewed the shareholder resolutions referred to on page 183 of the prospectus or any resolutions of the directors of the company authorizing the issuance of the New Shares. Please file a revised opinion or advise us as
RPRX answered
Under the UK Companies Act 2006, a resolution of shareholders of a public limited company (such as

Royalty Pharma plc) cannot be passed as a written resolution, but must instead be passed at a meeting of shareholders. A meeting of the shareholders of Royalty Pharma plc is due to take place on Saturday, June, 13, at which the resolutions

(currently in draft form and included in the documents reviewed by counsel) to authorize the directors of the company to issues shares in connection with the company’s IPO are expected to be passed. Amendment No.
Rest of the answer

3 refers to the resolutions concerned and the expectation they will be passed before closing of the offering, and the IPO would not proceed unless such authorities were in place by then.

Read in the reply
Recently adopted and issued accounting standards, page F-9
SEC asked (8)
Please have tax counsel revise its Exhibit 8.1 opinion to state clearly that the prospectus disclosure in these two sections are the opinion of named counsel. Also, revise the prospectus to reflect the same. Refer to Section III of Staff Legal Bulletin No. 19.
Rest of the question

In addition, please have tax counsel revise their 8.1 opinion to expressly consent to the reference to their firm under the caption “Legal Matters” in the prospectus, consistent with Section IV of Staff Legal Bulletin No. 19.

RPRX answered
The Company respectfully acknowledges the Staff’s comment, and, in response to the Staff’s comment, tax counsel has revised the Exhibit 8.1 opinion and page 200 of Amendment No. 3.
Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
8 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 23 letters filed since 2020-03-12. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.